| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000010548 |
| Receipt No. | R000012028 |
| Official scientific title of the study | Efficacy of Poststroke Intensive Rosuvastatin Treatment for Aortogenic Embolic Stroke (EPISTEME trial) |
| Date of disclosure of the study information | 2013/04/19 |
| Last modified on | 2016/11/03 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | Efficacy of Poststroke Intensive Rosuvastatin Treatment for Aortogenic Embolic Stroke (EPISTEME trial) | |
| Title of the study (Brief title) | Efficacy of Rosuvastatin therapy for aortogenic embolic stroke | |
| Region |
|
|
| Condition | |||
| Condition | Brain infarction or transient ischemic attack with atheromatous plaques in the aortic arch | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | We explore the efficacy of Rosuvastation for atheromatous plaque regression in the aortic arch and prevention of ischemic stroke and vascular diseases. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Morphological alteration of atheromatous plaques in the aortic arch |
| Key secondary outcomes | 1) Alteration of atheromatous plaques in the aortic arch
2) Changes in lipid profile 3) Changes in inflammatory markers and white blood cell count 4) Recurrence of ischemic stroke 5) Prevalence of hemorrhagic stroke including intracranial brain hemorrhage and subarachnoid hemorrhage 6) Prevalence of coronary artery disease 7) Other vascular diseases 8) Death |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | No treatment |
| Stratification | YES |
| Dynamic allocation | NO |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | NO |
| Concealment | Numbered container method |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Treatment with rosuvastatin 5mg daily | |
| Interventions/Control_2 | Treatment without rosuvastatin | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Patients with brain infarction or transient ischemic attack within 7 days after onset, having atheromatous aortic plaques greater than 4mm in size
2) Patients with hypercholesterolemia (Serum LDL-C levels greater than 140mg/dL) |
|||
| Key exclusion criteria | 1) Patients during pregnancy or lactation
2) Allergy against statin 3) Patients with coronary artery disease and requiring statin therapy 4) Patients with severe renal dysfunction or liver dysfunction 5) Patients undergoing cyclosporin therapy |
|||
| Target sample size | 100 | |||
| Research contact person | |
| Name of lead principal investigator | Yuji Ueno |
| Organization | Juntendo University Urayasu Hospital |
| Division name | Neurology |
| Address | Tomioka 2-1-1, Urayasu, Chiba, 279-0081, Japan |
| TEL | 0473533111 |
| yuji-u@juntendo.ac.jo | |
| Public contact | |
| Name of contact person | Yuji Ueno |
| Organization | Juntendo University Urayasu Hospital |
| Division name | Neurology |
| Address | 2-1-1, Tomioka, Urayasu, Chiba, Japan |
| TEL | 0473533111 |
| Homepage URL | |
| yuji-u@juntendo.ac.jo | |
| Sponsor | |
| Institute | Department of Neurology, Juntendo Universiy School of Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 順天堂大学医学部附属浦安病院、順天堂医院 |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000012028 |